Early research (Phase 1)Study completedNCT04818632What this trial is testingAZD9833 China PK StudyWho this might be right forER+, HER2-, Metastatic Breast Cancer AstraZeneca 28
Not applicableEnded earlyNCT05425550What this trial is testingEvaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.Who this might be right forBreast Cancer Palleos Healthcare GmbH 196
Not applicableLooking for participantsNCT06711068What this trial is testingAdjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target TherapyWho this might be right forHER2-positive Breast Cancer Shu Wang 8,077
Early research (Phase 1)Active Not RecruitingNCT05870579What this trial is testing[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT06001762What this trial is testingTRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerWho this might be right forBreast CancerEarly-stage Breast CancerHigh Risk Breast Carcinoma Dana-Farber Cancer Institute 90
Early research (Phase 1)Looking for participantsNCT05683418What this trial is testingEvaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerWho this might be right forHR+/HER2-negative Breast Cancer Totus Medicines 241
Not applicableUnknownNCT05870813What this trial is testingCLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast CancerWho this might be right forBreast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma Institut fuer Frauengesundheit 3,000
Post-approval studies (Phase 4)Not Yet RecruitingNCT07768358What this trial is testingTucatinib Continuation StudyWho this might be right forHER2-positive Breast CancerCervical CancerBiliary Tract Neoplasms+4 more Pfizer 175
Testing effectiveness (Phase 2)Study completedNCT01082068What this trial is testingStudy of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast CancerWho this might be right forBreast Cancer Sanofi 72
Testing effectiveness (Phase 2)Looking for participantsNCT07610720What this trial is testingDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerWho this might be right forAdvanced/Metastatic Breast CancerHER2-Positive Metastatic Breast Cancer Sun Yat-sen University 57
Testing effectiveness (Phase 2)Ended earlyNCT01776008What this trial is testingAkt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerWho this might be right forEstrogen Receptor PositiveHER2/Neu NegativeRecurrent Breast Carcinoma+5 more National Cancer Institute (NCI) 16
Not applicableLooking for participantsNCT07376174What this trial is testingThe Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted TherapyWho this might be right forBreast CancerHER2/CEP17 Ratio Shandong Cancer Hospital and Institute 300
Very early researchEnded earlyNCT00651976What this trial is testingLetrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by SurgeryWho this might be right forBreast Cancer Vanderbilt-Ingram Cancer Center 213
Large-scale testing (Phase 3)Study completedNCT04109391What this trial is testingExtension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03Who this might be right forHER2-positive Breast CancerEarly-stage Breast CancerBreast Cancer+3 more Tanvex BioPharma USA, Inc. 338
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05979220What this trial is testingStudy of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line ChemotherapyWho this might be right forBreast Cancer Shuangyue Liu 178
Early research (Phase 1)Ended earlyNCT03596658What this trial is testingSHR9549 in ER Positive HER2 Negative Advanced Breast CancerWho this might be right forER+ HER2- Advanced Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 4
Large-scale testing (Phase 3)Not Yet RecruitingNCT07061717What this trial is testingComparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerWho this might be right forHormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 474
Not applicableActive Not RecruitingNCT05036252What this trial is testingStudy of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild CardiotoxicityWho this might be right forBreast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast Cancer+5 more Memorial Sloan Kettering Cancer Center 23
Not applicableUnknownNCT02597868What this trial is testingA Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)Who this might be right forBreast Cancer Zhejiang Cancer Hospital 132
Not applicableActive Not RecruitingNCT04597580What this trial is testingPersonalised Disease Monitoring in Metastatic Breast CancerWho this might be right forBreast Cancer MetastaticEstrogen Receptor-positive Breast Cancer The Christie NHS Foundation Trust 97